Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: October 26, 2017
Pages: 97
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B214F8F47B5EN
Leaflet:

Download PDF Leaflet

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Biocon Ltd (Biocon) is a global biopharmaceutical company specialized in biopharmaceuticals and research services. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. Its core therapeutic areas include diabetes, cancer and autoimmune conditions. The company also provides research services which include discovery, development and manufacturing services for both small and large molecules. Biocon caters its research and development solutions to the biotechnology and pharmaceutical companies across the world. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Biocon Biologics India to Acquire Biosimilars Business from Biocon
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences
Venture Financing
Syngene May Raise Over USD50 Million in Venture Financing
Private Equity
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million
Partnerships
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation
Biocon Enters into Co-Development Agreement with Laboratorios PiSA
Saniona Enters into Agreement with Syngene
CytoSorbents Extends Co-Marketing Agreement with Biocon for CytoSorb
Syngene International Extends R&D Agreement with Bristol-Myers Squibb
Biocon Enters Into Co-Marketing Agreement With CytoSorbents For CytoSorb
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars
Abbott India Enters Into Joint Venture Agreement With Syngene International
Cellectis bioresearch Enters Into Co-Development Agreement With Syngene International
Syngene International Expands Co-Development Agreement With Endo Pharma
Licensing Agreements
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV
Biocon Enters into Licensing Agreement with Gilead Sciences
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb
Equity Offering
Syngene International to Raise up to USD87 Million in IPO
Asset Transactions
Biocon Biologics India to Acquire Biosimilars Business from Biocon
Acquisition
Biocon Completes Sale Of 78.4% Stake In AxiCorp For US$37.3 Million
Biocon Ltd - Key Competitors
Biocon Ltd - Key Employees
Biocon Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Recent Developments
Strategy And Business Planning
Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia
Financial Announcements
Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore
Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr
Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore
Oct 20, 2016: Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%
Jul 21, 2016: Biocon Reports a Strong Q1 FY17 Revenues at Rs. 952 Crore, Up by 11%; EBITDA Up 15% to Rs. 271 Crore; Net Profit Up 17% at Rs. 147 Crore
Apr 26, 2016: Biocon Q4FY16 Net Profit at Rs 361 Cr Revenue Crosses Rs 1,000 Cr; Up 17%
Apr 26, 2016: Biocon: Q4FY16 Net Profit at Rs 361 Cr; Revenue Crosses Rs 1,000 Cr; Up 17%
Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10%
Legal and Regulatory
Sep 18, 2017: Biocon's Facility in Vishakhapatnam completes USFDA Inspection with no observations
Jul 09, 2017: Biocon provides update on Bangalore Facility
Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency
May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited
Product News
12/01/2016: Proposed biosimilar drug shows potential as breast cancer treatment
08/25/2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency
07/21/2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
07/13/2017: FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocons Proposed Biosimilar Trastuzumab
03/13/2017: Mylan Announces Global Settlement and License Agreements with Genentech and Roche on Herceptin
03/03/2017: Biocon’s Statement on Delhi High Court Interim Order on Trastuzumab on March 3, 2017
Product Approvals
Sep 15, 2017: Mylan Announces Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)
Sep 15, 2017: Mylan Announces Withdrawal of the marketing authorisation application for Ogivri (trastuzumab)
Aug 30, 2017: USFDA Target Action Date for Trastuzumab Reset to December 3, 2017
Feb 16, 2017: U.S. FDA Accepts Biologics License Application for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
Jan 11, 2017: U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
Nov 08, 2016: Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab
Clinical Trials
Dec 27, 2016: Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data
Jun 03, 2016: Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology Annual Meeting
Jan 22, 2016: Biocon Announces Data from Key Studies for Insulin Tregopil - Positive Clinical Data Sets the Stage for Further Development by Biocon
Other Significant Developments
May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Biocon Ltd, Deals By Therapy Area, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017
Biocon Biologics India to Acquire Biosimilars Business from Biocon
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences
Syngene May Raise Over USD50 Million in Venture Financing
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation
Biocon Enters into Co-Development Agreement with Laboratorios PiSA
Saniona Enters into Agreement with Syngene
CytoSorbents Extends Co-Marketing Agreement with Biocon for CytoSorb
Syngene International Extends R&D Agreement with Bristol-Myers Squibb
Biocon Enters Into Co-Marketing Agreement With CytoSorbents For CytoSorb
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars
Abbott India Enters Into Joint Venture Agreement With Syngene International
Cellectis bioresearch Enters Into Co-Development Agreement With Syngene International
Syngene International Expands Co-Development Agreement With Endo Pharma
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV
Biocon Enters into Licensing Agreement with Gilead Sciences
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb
Syngene International to Raise up to USD87 Million in IPO
Biocon Biologics India to Acquire Biosimilars Business from Biocon
Biocon Completes Sale Of 78.4% Stake In AxiCorp For US$37.3 Million
Biocon Ltd, Key Competitors
Biocon Ltd, Key Employees
Biocon Ltd, Subsidiaries
Biocon Ltd, Joint Venture

LIST OF FIGURES

Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017
Skip to top


Ask Your Question

Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: